Prospects for pharmacological intervention in Alzheimer disease

Archives of Neurology

Volumn 57, Issue 4, 2000, Pages 454-459

  Emilien, Gérard ^a,d   Beyreuther, Konrad ^b   Masters, Colin L ^c   Maloteaux, Jean Marie ^a  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d NONE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; AMIRIDINE; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; CALPEPTIN; CHOLINESTERASE INHIBITOR; CYCLOOXYGENASE 2 INHIBITOR; DECAHYDRO 6 PHOSPHONOMETHYL 3 ISOQUINOLINECARBOXYLIC ACID; DONEPEZIL; ESTROGEN; FASORACETAM; GALANTAMINE; HEPTYLSTIGMINE TARTRATE; IDEBENONE; METRIFONATE; MONTIRELIN; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEFIRACETAM; NERVE GROWTH FACTOR; NEUROTROPIC AGENT; PHYSOSTIGMINE SALICYLATE; PRASTERONE; PROPENTOFYLLINE; RIVASTIGMINE; SELEGILINE; TACRINE; TALSACLIDINE; TALTIRELIN; UNINDEXED DRUG; [1 [(1 FORMYL 2 PHENYLETHYL)CARBAMOYL] 2 METHYLPROPYL]CARBAMIC ACID BENZYL ESTER;

ALZHEIMER DISEASE; ANTIOXIDANT ACTIVITY; CHOLINERGIC TRANSMISSION; DRUG EFFECT; DRUG METABOLISM; GASTROINTESTINAL SYMPTOM; HEADACHE; HORMONE SUBSTITUTION; HUMAN; INSOMNIA; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW;

EID: 0034076985     PISSN: 00039942     EISSN: None     Source Type: Journal    
DOI: 10.1001/archneur.57.4.454     Document Type: Review

References (30)

1. Jope RS, Song L, Powers RE. Cholinergic activation of phosphoinositide signaling is impaired in Alzheimer's disease brain. Neurobiol Aging. 1997;18:111-120.
2. Nitsch RM, Slack BE, Wurtman RJ, Growdon JH. Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors. Science. 1992;258:304-307.
3. Jossan SS, Adem A, Winblad B, Oreland L. Characterisation of dopamine and serotonin uptake inhibitory effects of tetrahydroaminoacridine in rat brain. Pharmacol Toxicol. 1992;71(3, pt 1):213-215.
4. Knapp MJ, Knopman DS, Solomon PR, Pendlerbury WW, Davis CS, Gracon SI, for the Tacrine Study Group. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. JAMA. 1994;271:985-991.
5. Tiseo PJ, Rogers SL, Friedhoff LT. Pharmacokinetic and pharmacodynamic profile of donepezil HCI following evening administration. Br J Clin Pharmacol Suppl. 1998;46:13-18.
6. Polinsky RJ. Clinical pharmacology of rivastigmine: a new-generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease. Clin Ther. 1998; 20:634-647.
7. Ringman JM, Cummings JL. Metrifonate (trichlorform): a review of the pharmacology, pharmacokinetics and clinical experience with a new acetylcholinesterase inhibitor for Alzheimer's disease. Expert Opin Invest Drugs. 1999;8: 463-471.
8. Rainer M. Galanthamine in Alzheimer's disease: a new alternative to tacrine? CNS Drugs. 1997;7:89-97.
9. Mielke R, Moller HJ, Erkinjuntti T, Rosenkranz B, Rother M, Kittner B. Propentofylline in the treatment of vascular dementia and Alzheimer-type dementia: overview of phase I and phase II clinical trials. Alzheimer Dis Assoc Disord. 1998; 12(suppl 2):S29-S35.
10. Parnetti L. Clinical pharmacokinetics of drugs for Alzheimer's disease. Clin Pharmacokinet. 1995;29:110-129.
11. Rogers SL, Perdomo C, Friedhoff LT. Clinical benefits are maintained during long-term treatment of Alzheimer's disease with the acetylcholinesterase inhibitor E2020. Eur Neuropsychopharmacol. 1995;5:386-387.
12. Gottwald MD, Rozauski RI. Rivastigmine: a brain-region selective acetylcholinesterase inhibitor for treating Alzheimer's disease. Expert Opin Invest Drugs. 1999; 8:1643-1682.
13. Itoh A, Nitta A, Katono Y, et al. Effects of metrifonate on memory impairment and cholinergic dysfunction in rats. Eur J Pharmacol. 1997;322:11-19.
14. Thomsen T, Bickel U, Fischer JP, Kewitz H. Galantamine hydrobromide in a long-term treatment of Alzheimer's disease. Dementia. 1990;1:46-51.
15. Ulrich J, Johannson-Locher G, Seiler WO, Stähelin HB. Does smoking protect from Alzheimer's disease? Alzheimer-type changes in 301 unselected brains from patients with known smoking history. Acta Neuropathol (Berl). 1997;94:450-454.
16. Müller WE, Mutschler E, Riederer P. Noncompetitive NMDA receptor antagonists with fast open-channel blocking kinetics and strong voltage-dependency as potential therapeutic agents for Alzheimer's dementia. Pharmacopsychiatry. 1995;28:113-124.
17. Winblad B, Poritis N. Memantine in severe dementia: results of the M-9 BEST Study (Benefit and Efficacy in Severely Demented Patients During Treatment With Memantine). Int J Geriatr Psychiatry. 1999;14:135-146.
18. Holtzman DM, Li Y, Chen K, Gage FH, Epstein CJ, Mobley WC. Nerve growth factor reverses neuronal atrophy in a Down syndrome model of age-related neurodegeneration. Neurology. 1993;43:2668-2673.
19. Mackenzie IR, Munoz DG. Nonsteroidal anti-inflammatory drug use and Alzheimer-type pathology in aging. Neurology. 1998;50:986-990.
20. Breitner JC, Welsh KA, Helms MJ, et al. Delayed onset of Alzheimer's disease with nonsteroidal anti-inflammatory and histamine H2 blocking drugs. Neurobiol Aging. 1995;16:523-530.
21. Rogers J, Kirby LC, Hempelman SR, et al. Clinical trial of indomethacin in Alzheimer's disease. Neurology. 1993;43:1609-1611.
22. Marcusson J, Rother M, Kittener B, et al. for the European Propentofylline Study Group. A 12-month, randomized, placebo-controlled trial of propentofylline (HWA 285) in patients with dementia according to DSM III-R. Dement Geriatr Cogn Disord. 1997;8:320-328.
23. Sano M, Ernesto C, Thomas RG, et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. N Engl J Med. 1997; 336:1216-1222.
24. Gutzmann H, Hadler D. Sustained efficacy and safety of idebenone in the treatment of Alzheimer's disease: update on a 2-year double-blind multicentre study. J Neural Transm Suppl. 1998;54:301-310.
25. Xu H, Gouras GK, Greenfield JP, et al. Estrogen reduces neuronal generation of Alzheimer β-amyloid peptides. Nat Med. 1998;4:447-451.
26. Hardy J, Israël A. Alzheimer's disease: in search of γ-secretase. Nature. 1999; 398:466-467.
27. Haass C, De Strooper B. The presenilins in Alzheimer's disease: proteolysis holds the key. Science. 1999;286:916-919.
28. Schenck D, Barbour R, Dunn W, et al. Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature. 1999;400:173-177.
29. Richard F, Helbecque N, Neuman E, Guez D, Levy R, Amouyel P. APOE genotyping and response to drug treatment in Alzheimer's disease. Lancet. 1997; 349:539.
30. Paganini-Hill A, Henderson VW. Estrogen replacement therapy and risk of Alzheimer disease. Arch Intern Med. 1996;156:2213-2217.